Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Haleh Chehrehgosha, Masoudreza Sohrabi, Faramarz Ismail‐Beigi, et al.
Diabetes Therapy (2021) Vol. 12, Iss. 3, pp. 843-861
Open Access | Times Cited: 110

Showing 1-25 of 110 citing articles:

Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)
Xiaohan Xu, Kyle L. Poulsen, Lijuan Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 191
Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease
Chander K. Negi, Pavel Babica, Lola Bajard, et al.
Metabolism (2021) Vol. 126, pp. 154925-154925
Open Access | Times Cited: 163
SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection
Θεόδωρος Ανδρουτσάκος, Narjes Nasiri‐Ansari, Athanasios‐Dimitrios Bakasis, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 6, pp. 3107-3107
Open Access | Times Cited: 93
SGLT2 inhibitor empagliflozin downregulates miRNA-34a-5p and targets GREM2 to inactivate hepatic stellate cells and ameliorate non-alcoholic fatty liver disease-associated fibrosis
Yunfeng Shen, Lidan Cheng, Minxuan Xu, et al.
Metabolism (2023) Vol. 146, pp. 155657-155657
Closed Access | Times Cited: 42
Pharmacological Approaches to Nonalcoholic Fatty Liver Disease: Current and Future Therapies
Idoia Genua, Kenneth Cusi
Diabetes Spectrum (2024) Vol. 37, Iss. 1, pp. 48-58
Open Access | Times Cited: 28
Efficacy of sodium glucose cotransporter 2 inhibitors on hepatic fibrosis and steatosis in non-alcoholic fatty liver disease: an updated systematic review and meta-analysis
A. Lopez, Janine Audrei T. Pajimna
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 17
Effects of empagliflozin on liver fat in patients with metabolic dysfunction–associated steatotic liver disease without diabetes mellitus: A randomized, double-blind, placebo-controlled trial
Ka Shing Cheung, Ho Yu Ng, Rex Wan Hin Hui, et al.
Hepatology (2024) Vol. 80, Iss. 4, pp. 916-927
Closed Access | Times Cited: 15
The efficacy of sodium-glucose transporter 2 inhibitors in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis
Hongsheng Li, Yanli Hou, Xin Wang, et al.
Pharmacological Research (2025) Vol. 213, pp. 107647-107647
Open Access | Times Cited: 1
Effect of SGLT-2 inhibitors on body composition in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials
Runzhou Pan, Yan Zhang, Rongrong Wang, et al.
PLoS ONE (2022) Vol. 17, Iss. 12, pp. e0279889-e0279889
Open Access | Times Cited: 57
SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease
Jun Sung Moon, Jun Hwa Hong, Yong Jin Jung, et al.
Trends in Endocrinology and Metabolism (2022) Vol. 33, Iss. 6, pp. 424-442
Closed Access | Times Cited: 43
Effect of sodium-glucose transporter 2 inhibitors on sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
Sha Zhang, Qi Zhan, Yidong Wang, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 30
The Effects of Sodium-Glucose Cotransporter 2-Inhibitors on Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease or Steatohepatitis and Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials
Cristina Bică, Roxana Adriana Stoica, Teodor Salmen, et al.
Medicina (2023) Vol. 59, Iss. 6, pp. 1136-1136
Open Access | Times Cited: 28
Effects of a Combination of Empagliflozin Plus Metformin vs. Metformin Monotherapy on NAFLD Progression in Type 2 Diabetes: The IMAGIN Pilot Study
Alfredo Caturano, Raffaele Galiero, Giuseppe Loffredo, et al.
Biomedicines (2023) Vol. 11, Iss. 2, pp. 322-322
Open Access | Times Cited: 25
Response to pioglitazone in non-alcoholic fatty liver disease patients with vs. without type 2 diabetes: A meta-analysis of randomized controlled trials
Zeyu Wang, Du Huiqing, Ying Zhao, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 25
Effects of SGLT-2 inhibitors on adipose tissue distribution in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials
Xianghong Wang, Niujian Wu, Chuanchuan Sun, et al.
Diabetology & Metabolic Syndrome (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 25
New anti-diabetic agents for the treatment of non-alcoholic fatty liver disease: a systematic review and network meta-analysis of randomized controlled trials
Tanawan Kongmalai, Varalak Srinonprasert, Thunyarat Anothaisintawee, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 24
Comparative efficacy of 5 sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor and 4 glucagon-like peptide-1 (GLP-1) receptor agonist drugs in non-alcoholic fatty liver disease: A GRADE-assessed systematic review and network meta-analysis of randomized controlled trials
Yunpeng Gu, Lei Sun, Wei Zhang, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 23
Management of Metabolic-Associated Fatty Liver Disease/Metabolic Dysfunction-Associated Steatotic Liver Disease: From Medication Therapy to Nutritional Interventions
M H Miran Beygi, Salma Ahi, Samaneh Zolghadri, et al.
Nutrients (2024) Vol. 16, Iss. 14, pp. 2220-2220
Open Access | Times Cited: 13
Insulin Resistance/Sensitivity Measures as Screening Indicators of Metabolic-Associated Fatty Liver Disease and Liver Fibrosis
Mohammad E. Khamseh, Mojtaba Malek, Soodeh Jahangiri, et al.
Digestive Diseases and Sciences (2024) Vol. 69, Iss. 4, pp. 1430-1443
Closed Access | Times Cited: 9
Inhibition of sodium-glucose cotransporter-2 and liver-related complications in individuals with diabetes: a Mendelian randomization and population-based cohort study
Sung Won Chung, Hye‐Sung Moon, Hyun‐Jae Shin, et al.
Hepatology (2024) Vol. 80, Iss. 3, pp. 633-648
Closed Access | Times Cited: 9
Risk of hepatic events associated with use of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists, and thiazolidinediones among patients with metabolic dysfunction-associated steatotic liver disease
Sungho Bea, Hwa Yeon Ko, Jae Hyun Bae, et al.
Gut (2024), pp. gutjnl-332687
Closed Access | Times Cited: 9
Review of current and new drugs for the treatment of metabolic-associated fatty liver disease
Robert G. Gish, Jian‐Gao Fan, Zahra Dossaji, et al.
Hepatology International (2024)
Closed Access | Times Cited: 8
Empagliflozin adjunct with metformin for the inhibition of hepatocellular carcinoma progression: Emerging approach for new application
A. M. Abdelhamid, Sameh Saber, Mahmoud E. Youssef, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 145, pp. 112455-112455
Open Access | Times Cited: 40
Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction‐associated fatty liver disease
Wah‐Kheong Chan, Soek‐Siam Tan, Siew‐Pheng Chan, et al.
Journal of Gastroenterology and Hepatology (2022) Vol. 37, Iss. 5, pp. 795-811
Open Access | Times Cited: 34
Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models
Sandra Feijóo‐Bandín, Alana Aragón‐Herrera, Manuel Otero-Santiago, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 10, pp. 5634-5634
Open Access | Times Cited: 34
Page 1 - Next Page

Scroll to top